Formulation Development
SCYNEXIS Announces Initiation of New Phase 3b Study to Evaluate Oral Ibrexafungerp as a Treatment for Complicated Vulvovaginal Candidiasis
SCYNEXIS, Inc. recently announced the initiation and first patient enrolled in a new Phase 3b, open-label, multicenter study (VANQUISH) to evaluate the efficacy, safety and tolerability…
Apellis Expands R&D Collaboration With Affilogic to Develop Targeted Complement Therapies for Delivery into the Brain
Apellis Pharmaceuticals, Inc. and Affilogic recently announced the companies have expanded their research and development (R&D) collaboration, which was initially formed in 2018, to include the development of Nanofitins….
Precision BioSciences Announces In Vivo Gene Editing Collaboration With Novartis
Precision BioSciences, Inc. recently announced it has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis Pharma….
Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC
Pasithea Therapeutics Corp. recently announced its acquisition of Alpha-5 integrin, LLC, a privately-held preclinical-stage company developing a monoclonal antibody (mAbs) for the treatment of amyotrophic lateral sclerosis (ALS) and….
Acrivon Therapeutics Receives FDA Clearance for Innovative Phase 2 Trial to Treat Ovarian, Endometrial & Urothelial Cancer Patients
Acrivon Therapeutics, Inc. recently announced the US FDA has cleared the company's Investigational New Drug (IND) application for its lead asset ACR-368 in a Phase…
USPTO Issues Patent Covering Use of XPro for Treatment of CNS Diseases
INmune Bio, Inc. recently announced the issuance of US Pat. No. 11,365,229 for METHODS OF TREATING NEUROLOGICAL DISEASES, a patent directed to use of Dominant…
Biomea Fusion Announces First Patient Dosed in Multiple Myeloma Cohort of COVALENT-101 Trial
Biomea Fusion, Inc. recently announced the first patient has been dosed in the MM cohort of COVALENT-101, the company’s Phase 1 clinical trial evaluating BMF-219,…
VIVEbiotech Continues Expansion of its Lentiviral Vector Manufacturing Capabilities to Address the Viral Vector Bottleneck
VIVEbiotech, S.L. recently announced its Good Manufacturing Practice (GMP)-accredited new facility is now fully operational after receiving the renewal of its GMP accreditation for a…
EyePoint Pharmaceuticals & OcuMension Therapeutics Announce Approval of NDA for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
EyePoint Pharmaceuticals, Inc. and OcuMension Therapeutics recently announced China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has approved YUTIQ (fluocinolone…
Halberd Creates Subsidiary to Apply Its Patented Technology to Treat Cancer
Recognizing the breadth of application of its patented extracorporeal treatment approach, Halberd Corporation recently announced the creation of a subgroup of researchers to focus on cancer treatment. ….
Acer Therapeutics & Relief Therapeutics Announce Update on US FDA Review of NDA
Acer Therapeutics Inc. and its collaboration partner, Relief Therapeutics recently announced the US FDA has issued a Complete Response Letter (CRL) regarding the New Drug…
Valneva & Pfizer Enter Equity Subscription Agreement & Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate
Valneva SE and Pfizer Inc. recently announced they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15…..
Hepion Pharmaceuticals Receives Orphan Drug Status Designation for the Treatment of Hepatocellular Carcinoma
Hepion Pharmaceuticals, Inc. recently announced the US FDA has granted Orphan Drug Designation to rencofilstat, a liver-targeting, orally administered, novel cyclophilin inhibitor, for the treatment…
VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
VYNE Therapeutics Inc. recently announced the completion of enrollment in the Phase 2a study of FMX114 for the treatment of mild-to-moderate atopic dermatitis (AD). FMX114…
Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease
Cyclerion Therapeutics, Inc. recently announced research from preclinical studies demonstrating treatment with its lead soluble guanylate cyclase (sGC) stimulator, CY6463, was associated with improved cellular…
INmune Bio, Inc. Presents Data on Combination Therapy With INB03 on Overcoming Resistance to HER2-Targeted Therapies in Breast Cancer
INmune Bio, Inc. has been invited to present data on reversing resistance to HER2-targeted immunotherapy at the HER2-Targeted Therapy Summit in Boston. Mucin 4 (MUC4),…
MD Anderson, Invectys and CTMC Announce Strategic Collaboration for CAR T Cell Therapy Development
The University of Texas MD Anderson Cancer Center, Invectys, Inc., and the Cell Therapy Manufacturing Center (CTMC), a joint venture between MD Anderson and National…
Aptamer Group Signs Deal With Flip Gene Therapeutics to Support the Development of Inducible Gene Therapies
Aptamer Group plc has recently negotiated a deal with the biotechnology company Flip Gene Therapeutics to support its novel, inducible gene therapy platform with the…
Kintara Therapeutics Granted Fast Track Designation for VAL-083 for Newly Diagnosed Glioblastoma
Kintara Therapeutics, Inc. recently announced the US FDA has granted Fast Track Designation (FTD) to Kintara’s VAL-083 for the treatment of patients with newly diagnosed…
Kindeva Drug Delivery Announces Collaboration With Synopsys
Kindeva Drug Delivery recently announced a collaboration with Synopsys, Inc. involving the implementation of Synopsys Simpleware automated software solutions to assist in creating….